title: Testosterone and Male Infertility.
abstract: Hypogonadism and its therapies have a significant impact on male fertility potential. It is necessary to determine the etiology to treat and counsel the patient appropriately on therapeutic options. For the hypogonadal male on exogenous testosterone, management should begin with cessation of the exogenous testosterone and supplemental subcutaneous human chorionic gonadotropin and an oral follicle-stimulating hormone (FSH)-inducing agent to allow reestablishment of the hypothalamic-pituitary-gonadal axis and spermatogenesis. Further supplemental therapy with recombinant FSH in some patients may be necessary to achieve optimal semen parameters.
authors.affiliation: Division of Male Reproductive Medicine and Surgery, Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: Samuel J
authors.initials: SJ
authors.lastname: Ohlander
authors.affiliation: Division of Male Reproductive Medicine and Surgery, Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: Mark C
authors.initials: MC
authors.lastname: Lindgren
authors.affiliation: Division of Male Reproductive Medicine and Surgery, Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: larryl@bcm.edu.
authors.forename: Larry I
authors.initials: LI
authors.lastname: Lipshultz
mesh_terms: D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D007248:Infertility, Male / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D013739:Testosterone / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D013739:Testosterone
keywords: Exogenous; Hypogonadism; Hypogonadotropic; Infertility; Spermatogenesis; Testosterone